PT  - JOURNAL ARTICLE
AU  - Yoshiki Shiraishi
AU  - Koichiro Asano
AU  - Takeshi Nakajima
AU  - Tsuyoshi Oguma
AU  - Yusuke Suzuki
AU  - Tetsuya Shiomi
AU  - Koichi Sayama
AU  - Kyoko Niimi
AU  - Misa Wakaki
AU  - Junko Kagyo
AU  - Eiji Ikeda
AU  - Hiroyuki Hirai
AU  - Kazuhiro Yamaguchi
AU  - Akitoshi Ishizaka
TI  - Prostaglandin D<sub>2</sub>-Induced Eosinophilic Airway Inflammation Is Mediated by CRTH2 Receptor
AID  - 10.1124/jpet.104.078212
DP  - 2005 Mar 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 954--960
VI  - 312
IP  - 3
4099  - http://jpet.aspetjournals.org/content/312/3/954.short
4100  - http://jpet.aspetjournals.org/content/312/3/954.full
SO  - J Pharmacol Exp Ther2005 Mar 01; 312
AB  - Mast cell-derived prostaglandin D2 (PGD2) is one of the essential modulators of eosinophilic airway inflammation in asthma and allergic rhinitis. Two G protein-coupled receptors for PGD2, prostaglandin D2 receptor (DP) and chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2), are both expressed on the surface of eosinophils, and CRTH2 has been demonstrated to mediate PGD2-induced eosinophil mobilization in vitro. However, it has not yet been determined whether PGD2 and its receptors mediate in vivo eosinophil trafficking into the airways or other organs. We demonstrated that intratracheal administration of PGD2 in rats pretreated with systemic interleukin-5 (IL-5) injection induced marked airway eosinophilia, determined by the differential counts of cells in bronchoalveolar lavage (BAL) fluid and lung histology, within 2 h. Systemic IL-5 alone significantly increased the number of eosinophils in the peripheral blood but showed no effect on airway eosinophilia. Three CRTH2-specific agonists (13,14-dihydro-15-keto-PGD2, 11-deoxy-11-methylene-15-keto-PGD2, and indomethacin) demonstrated equivalent induction of BAL eosinophilia to that of PGD2, but a DP agonist (BW 245C [5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl)-hydantoin]) or a thromboxane A2 receptor (TP) agonist ([1S-1α,2β(5Z), 3α(1E,3R*),4α)]-7-[3-(3-hydroxy-4-(4′-iodophenoxy)-1-butenyl)-7-oxabicyclo-[2.2.1]heptan-2-yl]-5-heptenoic acid) showed no effect. PGD2 or CRTH2 agonist-induced BAL eosinophilia was almost completely inhibited by pretreatment with a CRTH2/TP antagonist, ramatroban [BAY-u3405; (+)-(3R)-3-(4-fluorobenzenesulfonamido)-1,2,3,4-tetra-hydrocarbazole-9-propionic acid], whereas a TP-specific antagonist, SQ29,548 (5-heptenoic, 7-[3-[[2-[(phenylamino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2.2.1]-hept-2-yl]-[1S-[1α,2α(Z),3α,4α]]), or a DP-specific antagonist, BW A868C [3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexy-2-hydroxyethylamino)-hydantoin], did not inhibit the effects of PGD2. These results suggest that CRTH2 plays a significant role in the eosinophil trafficking from the bloodstream into the airways in PGD2-related airway inflammation. The American Society for Pharmacology and Experimental Therapeutics